Polaris Group
http://polarispharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Polaris Group
Lykos’ MDMA NDA Leads Upcoming Tests Of US FDA’s Psychedelics Draft Guidance
Pipeline is concentrated around Phase II, but sponsors have a few chances to see how FDA handles its ‘foundational constructs’ for psychedelic drugs, led by Lykos’ pending NDA for PTSD and Compass Pathways’ Phase III synthetic psilocybin COMP360 for treatment-resistant depression.
Finance Watch: October Begins With A VC Mega-Round For Newly Named Iambic
Private Company Edition: Iambic, formerly known as Entos, closed a $100m series B venture capital round to advance its AI-discovered therapeutics. Also, Evozyne raised $81m and Acesion brought in €45m in series B rounds, while Mogrify added $10m to bring its series A to $46m.
$100m+ China Biotech VC/PE Financings Return In July
Pyrotech Therapeutics and Worg Pharmaceuticals are among the few Chinese biotechs to have bagged fresh large funding round from venture capital and private equity investors over the past month.
Asia Deal Watch: Kelun Partners With Merck A Third Time, Optioning Rights To Seven ADCs
Already partnered on antibody-drug conjugates and a Phase III breast cancer candidate, Merck could pay up to $9.3bn under its third pact in 2022 with Kelun. Eisai divests Fycompa to Catalyst.
Company Information
- Industry
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Antisense, Oligonucleotides
- Other Names / Subsidiaries
-
- Polaris Pharmaceuticals, Inc.
- TDW Pharmaceuticals, Inc.
- DesigneRx Pharmaceuticals, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice